trending Market Intelligence /marketintelligence/en/news-insights/trending/ag1o-1gq9w_5jwkuz5cala2 content esgSubNav
In This List

Pfizer hair loss drug wins US FDA breakthrough therapy designation

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Pfizer hair loss drug wins US FDA breakthrough therapy designation

Pfizer Inc. said the U.S. Food and Drug Administration granted the breakthrough therapy designation to its hair loss medicine PF-06651600.

The New York-based pharmaceutical giant's PF-06651600 is intended to treat patients with alopecia areata, a chronic autoimmune skin disease that causes hair loss on the scalp, face or body.

There are no FDA approved treatments for alopecia areata, which impacts millions of people worldwide.

Under the FDA's breakthrough therapy designation, the regulator expedites the development and review of drugs that demonstrate substantial improvement over existing therapies to treat a serious or life-threatening disease or condition.

Pfizer said the U.S. regulator granted the designation based on data from a phase 2 trial, results from which will be released at the 27th European Academy of Dermatology and Venerology Congress in Paris later this month.